Thanks for nothing Novartis. From Alcon

Discussion in 'Novartis' started by anonymous, Sep 22, 2015 at 10:46 PM.

  1. anonymous

    anonymous Guest

    How apparent is it now Novartis has no clue how to run a small specialty company. Freaking ruined. Haven't made numbers since you guys purchased us, can't forecast jack and we are bleeding talent b/c you run everyone off. We were doing just fine before you had to come in and pay about $1,000,000,000 too much for us. Nestle must laugh at you guys every single day. We were killing it when those little Swiss chocolate makers let us run our own show. Totally hands off and everybody made $$$$$. Thanks for nothing, sure do know how to ruin a good thing. And so far as I can tell that's all you know how to do. Jackasses.

    Good luck ever understanding the surgical business. It probably like a magic show to a 4yr old.
     

  2. anonymous

    anonymous Guest

    Jeff George, head of Alcon is American, not swiss? Jeff George is very talented, if talented means getting promoted because daddy George was on the Board.
     
  3. anonymous

    anonymous Guest

    stop talking shit.
     
  4. anonymous

    anonymous Guest

    Jeff George has been Division Head of Alcon since May 1, 2014. Heis a member of the Executive Committee of Novartis.

    Mr. George received a Master of Business Administration fromHarvard University in 2001. He graduatedin 1999 with a master’sdegree from The Johns Hopkins University’s School of Advanced International Studies, where he studied international economicsand emerging markets political economy. In 1996, he received hisbachelor’s degree, magna cum laude, in in ternational relations fromCarleton College in Minnesota, United States.

    -> Bill George is professor of management practice at Harvard Business School, where he has taught leadership since 2004.

    Mr. George currently serves as director of ExxonMobil, Goldman Sachs, and the Mayo Clinic and also served on the board of Novartis
     
  5. anonymous

    anonymous Guest

    those are some juicy conflicts of interest indeed.
    and quite the paradox.
    serving on the board of one company that cares and cures, while the other increases the concentration of C02 in the atmosphere.
     
  6. anonymous

    anonymous Guest

    Having a fancy degree and being successful is leading a company are apples and oranges. Daddy buy him those pretty pieces of paper?
     
  7. anonymous

    anonymous Guest

    why do pieces of paper need to be bought?

    why not earned?
     
  8. anonymous

    anonymous Guest


    I would take George of Andrin any day....He single handedly destroyed Vaccines...Alcon is up next...

    good luck
     
  9. anonymous

    anonymous Guest

    Joe blames Alcon for bringing their Q3 earnings down, but mentioned nothing about the almost half a billion dollar kickback lawsuit he settled.
     
  10. anonymous

    anonymous Guest

    the fall of Alcon is because the lack of understanding of Surgical business and running it like PH. Implementation of PH policies in surgical led the fall and it spiraled and hit PH SOV also.

    Arm Chair lawyers and accountants preparing company business strategy where in professionals built the company are sidelined. Most ELT or regional LT has minimal or zero experience in ophthalmology itself! and more over making Alcon a Novartis colony as if there is no one to lead this company which was growing high for 65% years. and after colonization first time hit minus double digit growth!

    What else you expect? 12% growth? i think -12% - still the 55Bio invested investors are lucky! its time investors ask tough questions to both JGs!
     
  11. Alcon employees..

    A few years ago, when novartis first acquired Alcon, I warned you that the execs at novartis do not know how to run a business. ANY business. I warned you that novartis would RUIN Alcon. It appears they have. No surprise there. But the execs are happy. They have no intention to run a pharm business. They are venture capitalists, NOT scientists or researchers or anyone who cares about health care. Their goal is to acquire companies, strip what is valuable from it, trash what is not generating immediate cash (R&D) and sell off anything that is left.
     
  12. anonymous

    anonymous Guest

    Joe can only blame himself for Alcon being... the CEO during integration and subsequent 5 years... What did he do? Where is the growth and product pipeline?

    He stayed in his ivory tower, managing Alcon from distance.
     
  13. anonymous

    anonymous Guest

    Well it looks like you begin gutting us next month.
     
  14. anonymous

    anonymous Guest

    Bullseye. Nailed it. 100% accurate. Well done.
     
  15. anonymous

    anonymous Guest

    The Novartis purchase/takeover of Alcon will always be seen as the line of demarcation between success and complete & utter failure. Not one good thing, not one has happened since that time. We are like a dead man walking. It's only a matter of time and how far we can limp.

    Thanks for nothing NVS. Nice job with your stock too...like the Titanic. Meanwhile our old competitor Allergan is at $317. Well done you've been a great parent company. Good God.
     
  16. anonymous

    anonymous Guest

    Alcon is dying a slow and painful death under NVS, they do not understand Alcon's business, its history, our customers nor the market. They fill key positions with people who have no clue as to Alcon's business situation. By the time they get up to speed, Alcon will be dead beyond any hope of rescue. Sell it now NVS before it turns into dust and takes your stock price down with it.
     
  17. anonymous

    anonymous Guest

    Would a buyer performing a proper due diligence be willing to buy it? No way, i think NVS will have to stick this one out, keep their fingers crossed and ride it to the ground. Or just maybe dad can help son out and persuade a rich friendly company to buy at the right price?
     
  18. anonymous

    anonymous Guest

    Under Schollmiaer, Sisson and other Alcon greats we were number one in industry top 500 in places to work and now with the stupid liberal ideas of novaritis not even on the radar so you tell me does any degree actually matter I have a thousand examples of no it doesn't if you do not have common sense to match
     
  19. anonymous

    anonymous Guest

    It should be the other way around really. Alcon should blame Novartis for bringing it down with idiotic management practices that have totally destroyed Alcon's competitiveness.
     
  20. anonymous

    anonymous Guest

    NBS alone is enough to bring any company to its knees